Hemophilia is a genetic disorder where the body fails to coagulate blood when blood vessel is ruptured. Between itsvariants, hemophilia A is more common than hemophilia B. A very rare form of hemophilia namely acquired hemophilia results from abnormalities in immune system of an individual. Acquired hemophilia is not a genetic disorder. Common symptoms of hemophilia are internal and external bleeding episodes.
Based on the treatment of hemophilia, global hemophilia therapeutics market is segmented as follows:
- Hemophilia A
- Hemophilia B
The global hemophilia market is further segmented on the basis of medicines used in its treatment which are as follows:
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1937
In addition, many market players are focusing on development of gene therapy, not only to treat hemophilia but to cure the disease completely. Apart from octocog Alfa, nonacog Alfa, desmopressin, many drugs are currently in pipeline and upcoming approval of these pipeline drugs will drive the hemophilia therapeutics market towards growth in the near future. Lack of awareness about the disease and available treatment and high cost of available drugs are the major factors that are restraining the growth of the global hemophilia therapeutics market.
Geographically, the global hemophilia therapeutics market can be segmented on the basis following regional distribution:
- North America
- Asia Pacific
- Rest of the World
Currently, North America dominates the global hemophilia therapeutics market and is followed by Europe due to high rates of awareness about the available hemophilia treatments. Asia-Pacific is a promising market for hemophilia therapeutics and is expected to undergo rapid market growth due rapidly developing medical tourism industry, increase in purchasing power, rapidly improving healthcare infrastructure and increased awareness about overall healthcare and the available treatments. Some of the major companies contributing to global hemophilia therapeutics market are Pfizer Inc., Swedish Orphan Biovitrum AB, Baxter International Inc., Novo Nordisk A/S. and Bayer AG.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453